What Rare Disease Day Means to Trinity Partners

Rare Disease Day falls on Wednesday, February 28th. At Trinity, we work closely with many life sciences companies developing treatments for rare disease patients. Research is crucial to the rare community, and we are committed to help raise awareness around the importance of medical representation for individuals with rare diseases and their families. Keep an eye on our social media channels this week for some rare disease-focused updates and read on to learn what Rare Disease Day means to Trinity employees:

“I hope that, one day, rare diseases have as many treatment options and cures as any other disease. Rare diseases deserve to receive attention and be understood like any other condition.” Rachel Halperin, Senior Associate Consultant

“From helping companies develop business cases for rare inherited disorders, to my personal life where I function as a caretaker for a loved one with a rare autonomic/hypermobility disorder, I deal with the challenges presented by rare diseases on a daily basis. I hope that the pharmaceutical ecosystem continues to evolve so that the business cases for these agents become more attractive, spurring innovation in underserved patient populations.”  Consultant

“Rare Disease Day is a reminder of the millions of patients and families affected by rare diseases. It’s also a reminder of how the treatment of rare disease is catalyzing innovations that will revolutionize treatment of rare and non-rare diseases.” Herman Sanchez, Partner

“[Rare Disease Day means] that no one gets left behind. Just because it is a rare disease doesn’t mean we don’t care. I hope more companies will invest in rare diseases and find help for patients who have been overlooked all this time.” Nandini Hadker, Principal

“Rare Disease Day means raising worldwide awareness of rare conditions to help improve the ability to identify and diagnose patients and increase research and development to find effective treatments.  I’ve personally watched my brother struggle for years to find a cause for his symptoms and, now diagnosed with a rare disease, he continues to suffer due to lack of treatments. I hope for him and all others with rare diseases that research continues and the great progress over recent years continues.” Maria Gumina, PhD, Engagement Manager

“Rare Disease Day means an opportunity to recognize the tireless work and strength of communities across the world who fight for recognition and awareness of their conditions that consume their lives. A good friend of mine has Phenylketonuria (PKU), and I’ve seen her overcome obstacles in her everyday life that most people never face. In researching rare diseases as a focus of my work, I’ve learned to be so much more grateful and feel so much more blessed to have two happy, healthy children.” Krista Perry, Principal

Trinity Partners Principal Jillian Godfrey Scaife Discusses Trinity Biosimilar Whitepaper

In a recent article for Managed Healthcare Executive, editor Tracey Walker spoke with Trinity’s Jillian Godfrey Scaife about the findings of Trinity’s recent biosimilar whitepaper. In the article, Jillian highlights key takeaways from the findings. You can read the full story including further insights from Jillian here: http://bit.ly/2Br1FsD

New Report from Trinity Partners Highlights Key Barriers to U.S. Biosimilar Adoption

Complex Pricing Structures, Legal and Regulatory Barriers,
and Clinical Uncertainty Hinder Progress in Biosimilar Market Access

Key findings from the report, which seeks to reveal opportunities to accelerate biosimilar adoption, include the following:

  • Biosimilar pricing to date has not offered the sharp discounts payers expect, after accounting for contract discounts and nuances such as the “rebate trap”;
  • Biologic innovators have taken legal and promotional actions that derail biosimilar commercial success;
  • Providers are not fully comfortable with biosimilars and are interested in seeing more clinical and real-world data; if biosimilars were to attain interchangeability status, this gap in clinical comfort could be minimized

The report, conducted in partnership with Schlesinger Associates, is supported by findings from qualitative market research with medical directors at payer organizations in the United States. The findings are based on historical trends, current market dynamics, and future market access expectations in biosimilars.

“Biosimilar access still lags behind traditional small molecule markets, but there is so much potential for long-term cost savings for payer plans and the U.S. healthcare system as a whole,” said Neal Dunn, Partner, Trinity Partners. “Once interchangeability is achieved, other barriers such as clinical confidence and litigation will fall into place.”

“Each country’s commercial and regulatory landscape is nuanced based on laws, pay structures, and culture, which creates unique environments for market access,” said John Corcoran, Founder and President, Trinity Partners. “Our in-depth knowledge of the U.S. market provides us with unique insights that allow us to optimally navigate those channels to achieve market access as quickly as possible, thus providing treatments to patients who need them the most.”

To view the full research report, click here.

About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about Trinity Partners, click here.

Trinity’s John Greenway and Nick Simmons-Stern to Present Case Study at CBI’s Biosimilar Summit

John Greenaway, Jillian Scaife, Nick Simmons-Stern, Ali Haber, and Christina Danosi are traveling to Alexandria, Virginia this week to attend CBI’s Biosimilars Summit. At the conference, they’ll discuss how to overcome reimbursement hurdles in an expanding U.S. biosimilars market. Learn more about the event here: http://www.cbinet.com/conference/pc18014

Trinity Partners Director of Advanced Analytics, Todd Foster to Attend PMSA’s Winter Symposium

Todd Foster, Trinity’s director of advanced analytics, will attend the PMSA’s Multi-Channel Marketing Symposium in Las Vegas, January 18 – 19 2018. During the event, Todd will meet with fellow industry leaders to discuss innovative marketing practices that use data to elevate multi-channel marketing for the biotechnology, medical and pharmaceutical industries. Learn more about the event here: http://bit.ly/2FIL3MS

Trinity Partners Founder and President, John Corcoran Discusses Drug Affordability in 2018

In a recent article for Managed Healthcare Executive, reporter Mari Edlin spoke with Trinity’s John Corcoran about what he sees in the pipeline for 2018 in terms of drug affordability and pharma’s response to the matter. You can read the full article including further insights from John, here: http://bit.ly/2DHZpwg

Senior Partner Leslie Sandberg Orne Discusses Top Drugs for 2018

In a recent article for Formulary Watch, editor Christine Blank spoke with Trinity’s Leslie Sandberg Orne about new blockbuster drugs to hit the marketplace in 2018 that will treat HIV, diabetes, cancer, migraine headaches and other conditions. Check out Leslie’s insights in the full article, here: http://bit.ly/2ArPeZz

Trinity’s Herman Sanchez, Alex Chiang and Vivian DeWoskin attended the American Society of Hematology (ASH) Annual Meeting in Atlanta

On December 9th, Trinity’s Herman Sanchez, Alex Chiang and Vivian DeWoskin attended the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA. During the meeting, Trinity employees had the opportunity to receive insight on evidence-based practice and decision making around malignant and non-malignant hematology, as well as the controversies associated with diagnosis and management. A full agenda of the annual meeting
can be found here: http://bit.ly/2zCT0Q5

Our Managing Partner Dave Fitzhenry recently sat down with Brian Orelli from BioWorld Insight

Our Managing Partner Dave Fitzhenry recently sat down with Brian Orelli from BioWorld Insight where he discussed the findings of our second annual Drug Index. In the article titled, “Winners and losers from the FDA approval class of 2014,” Dave provided a comprehensive overview of the commercial success and performance of each individual drug humorously highlighting how Trinity Partners “envisioned it like looking at NFL draft grades.”

Experts from Trinity Partners and Janssen Publish Article in Dermatology and Therapy

A team of experts from Trinity Partners and Janssen have published an article in Dermatology and Therapy. The paper, titled, “Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis,” describes the results of a study to determine dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. The study concluded that comprehensive education regarding treatment attributes may help minimize the influence of subjective biases and facilitate appropriate and patient-centered treatment selection in psoriasis.

The paper was authored by Gordon Lau, Gretchen R. Chiu, Nandini Hadker, Aparna Deshpande, Stephen Fleming, and Nicola Vance, all of Trinity Partners, along with Seina Lee and Steve Fakharzadeh of Janssen Scientific Affairs. At the time of the study, Matthew Alcusky was a postdoctoral fellow with Thomas Jefferson University and Janssen Scientific Affairs.

To view the full text of the article, please visit http://bit.ly/2hJqe9k